POWERED BY

All are welcome to request manual stroke prevention, health viewpoint magazine (urology care), intended to please negotiate Bridge PR 02-25068359 or letter nathanlu@mbpr.com.tw
News (33) Ophthalmology (909) Dental (411) Cancer (1059) epidemic (1063) nervous system (675) spiritual system (0) of the urinary system (578) Skin System (785) reproductive system peptide bond (591) Plastic Surgery (785) ENT system (223) rheumatism immune system (589) Respiratory (476) cardiovascular system (727) gastrointestinal hepatobiliary system (711) of the musculoskeletal system (38) DNA genetic inheritance (140) Blood and Oncology Systems (185) endocrine cum metabolic system (400) Sleep Health (5) Health Health (28) Female Gynecology (2) Chinese health peptide bond (1) Drug Safety (802) Health Slimming (10) Food Safety (797) Mental Health (553) Health Food (357) Food newly discovered (14) medical system and regulation (643) Other (1691) Respiratory digestive system (11) of the immune system (247) healthy small Piebu (1) Health Small Piebu (157) Gu liver newsletter (0) No Project REVIEW medicine. learning. miscellaneous. peptide bond chi (6) Spring No. (22) Autumn No. (22) 2007 2008 2009 Fall No. (18) review peptide bond Excerpts (2) magazine electronic gear (0) Medicine REVIEW (15) health perspective (a) health point of view (11) Other (1) health perspective autumn No. 2008 (14) Uncategorized (439)
Monthly article collection
Oct 2014 (2) Sep 2014 (1) Aug 2014 (7) Feb 2014 (19) Jan 2014 (18) Dec 2013 (44) Nov 2013 (5) Aug 2013 (9) Jul 2013 (64) May 2013 (18) Apr 2013 (24) Mar 2013 (22) Feb 2013 (13) Jan 2013 (83) Dec 2012 (1) Nov 2012 (24) Oct 2012 (15) Sep 2012 (6) Aug 2012 (241) Jul 2012 (177) May 2012 (134) Apr 2012 (111) Mar 2012 (118) Feb 2012 (136) Jan 2012 (63) Dec 2011 (60) Nov 2011 (68) Oct 2011 (113) Aug 2011 (43) Apr 2011 (5) Mar 2011 (19) Feb 2011 (5) Jan 2011 (9) Dec 2010 (3) Nov 2010 (11) Oct 2010 (5) Sep 2010 (28) Aug 2010 (67) Jul 2010 (8) Jun 2010 (5) Apr 2010 (52) Feb 2010 (1) Jan 2010 (68) Dec 2009 (38) Nov 2009 (14) Oct 2009 (5) Sep 2009 (69) Aug 2009 (30) Jul 2009 (98) Jun 2009 (327) May 2009 (105) Apr 2009 (394) Mar 2009 (712) Feb 2009 (887) Jan 2009 (450) Dec 2008 (630) Nov 2008 (365) Oct 2008 (17) Sep 2008 (389) Aug 2008 (943) Jul 2008 (1250) Jun 2008 (580) May 2008 (293) Apr 2008 (387) Mar 2008 (310) Feb 2008 (189) Jan 2008 (267) Dec 2007 (313) Nov 2007 (435) Oct 2007 (623) Sep 2007 (458) Aug 2007 (224) Jul 2007 (42) Jun 2007 (153) May 2007 (424) Apr 2007 (469) Mar 2007 (549) Feb 2007 (245) Jan 2007 (774) Dec 2006 (457) Nov 2006 (444) Oct 2006 (34) May 2006 (1) (3)
POWERED BY
(CNA messaging services 20080606 11:16:15,) Business Wire June 3, 2008, New Jersey Summit (SUMMIT) reported - Celgene Corporation (Nasdaq: CE LG) today VIDAZA in patients with myelodysplastic syndrome a phase III international clinical trials conducted in vivo results announced update: This study showed that, compared with conventional therapy (CCR), VIDAZA can prolong overall survival time. The result is the 44th annual peptide bond meeting of the American Society of Clinical Oncology in Chicago, Illinois, USA, held on published.
May 2004, VIDAZA became FDA approved treatment of myelodysplastic syndromes (MDS) patients first drug. FDA approved VIDAZA is a new type of drug formulations peptide bond demethylation first drug for the treatment of all five MDS subtypes, including low-risk and high-risk patients. These subtypes include: refractory anemia (RA) or refractory anemia with ring sideroblasts bud cells (RARS), when accompanied by neutropenia or thrombocytopenia or disease requiring transfusions; refractory anemia with excess blasts ( RAEB), refractory anemia with excess blasts - transformed (RAEB-T), and chronic myeloid - monocytic myeloid leukemia (CMMoL). peptide bond
It is believed that, VIDAZA produce anti-tumor effect was produced by hypomethylation of DNA and of the bone marrow to produce abnormal hematopoietic cells play a direct cytotoxic effect. VIDAZA in vitro inhibition of the maximum concentration required for DNA methylation and will not seriously inhibit DNA synthesis. DNA hypomethylation may restore normal function to those of cell differentiation and proliferation genes play an important role. VIDAZA cytotoxicity of rapidly dividing cells (including those of cancer cells to normal growth peptide bond control mechanisms lost reactions) have lethal effects, non-proliferating cells are relatively insensitive to VIDAZA. VIDAZA was approved in January 2007 for intravenous administration.
Myelodysplastic syndromes (MDS) are a group of hematologic malignancies that affect approximately 300,000 people worldwide. When the blood cells in the bone marrow sustained in a non-proliferative or severe maturity, and will never develop into capable of performing their necessary functions of mature cells, will produce myelodysplastic syndrome. Finally, the bone marrow may be filled with blast cells suppressing normal cell development. peptide bond According to the American Cancer Society statistics, MDS United States each year 10,000 to 20,000 new cases diagnosed, the average survival time is about six months to six years (the length depends on the specific type of MDS). MDS patients must often rely on blood transfusions to treat the symptoms of anemia and fatigue, and frequent blood transfusions will likely cause life-threatening iron overload or iron poisoning, so they desperately need new treatments for the cause, not just limited to simple symptomatic treatment .
This press release contains certain forward-looking statements, which involve a number of factors known or unknown risks, delays, uncertainties and other companies can not control, which may cause the actual results, performance or achievements The results of these forward-looking statements covered by the emergence of a significant difference between the performance or other expectations. These factors include the current or the United States Food and Drug Administration or other regulatory authorities pending the results of research and development activities or behavior, and the company's filings with the Securities and Exchange Commission documents (such as Form 10-K, 10-Q and 8-K factors) as detailed in reports.
Contact: Senior Vice President and Chief Financial Officer of Celgene CorporationDavid Gryska peptide bond Phone: 908-673-9059 or Brian P. Gill, vice president of Corporate Communications Department Tel: 908-673-9530